TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc. is a clinical-stage biotechnology company based in Boston, Massachusetts, focused on developing RNA-based therapeutics and immuno-oncology treatments for high-risk and advanced cancers. The company's mission is to deliver a cancer-free future by overcoming challenges in the targeted delivery of therapeutics, believing that cancer can be effectively treated through the intelligent design and efficient delivery of RNA therapies.

TransCode's core offerings revolve around its proprietary TTX nanoparticle delivery platform. Its lead therapeutic candidate, TTX-MC138, is an antisense inhibitor designed to target microRNA-10b (miR-10b), which is considered a master regulator of metastatic cell viability in various cancers, including breast, pancreatic, ovarian, colon cancer, and glioblastomas. The company also has a pipeline of other preclinical programs, including TTX-siPDL1, TTX-RIGA, and TTX-siMYC, and has expanded its portfolio to include a cancer vaccine candidate (Seviprotimut-L) and an oncolytic immunotherapy platform.

In recent news, TransCode Therapeutics successfully completed its Phase 1a clinical trial for TTX-MC138, reporting favorable safety and stabilization data in metastatic cancer patients. Following this, the company initiated a Phase 2a clinical trial for TTX-MC138 in patients with ctDNA positive colorectal cancer, in collaboration with Quantum Leap Healthcare Collaborative. Philippe P. Calais serves as the CEO and Executive Chairman of the Board. The company, which is publicly traded on NASDAQ under the ticker RNAZ, has a market capitalization of approximately $4.72 million as of June 2026.